FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953696397> ?p ?o ?g. }

• W2953696397 endingPage "e0217701" @default.
• W2953696397 startingPage "e0217701" @default.
• W2953696397 abstract "The last international consensus on the management of type 2 diabetes (T2D) recommends SGLT-2 inhibitors or GLP-1 agonists for patients with clinical cardiovascular (CV) disease; metformin remains the first-line glucose lowering medication. Last studies suggested beneficial effects of SGLT-2 inhibitors or GLP-1 agonists compared to DPP-4 inhibitors, in secondary CV prevention. Recently, a potential benefit of SGLT-2 inhibitors in primary CV prevention also has been suggested. However, no comparison of all the new and the old hypoglycemic drugs is available on CV outcomes. We aimed to compare the effects of old and new hypoglycemic drugs in T2D, on major adverse cardiovascular events (MACE) and mortality.We conducted a systematic review and network meta-analysis of clinical trials. Randomized trials, blinded or not, assessing contemporary hypoglycemic drugs on mortality or MACE in patients with T2D, were searched for in Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov. References screening and data extraction were done by multiple observers. Each drug was analyzed according to its therapeutic class. A random Bayesian network meta-analysis model was used. The primary outcomes were overall mortality, cardiovascular mortality, and MACE. Severe adverse events and severe hypoglycemia were also recorded. 175,966 patients in 34 trials from 1970 to 2018 were included. No trials evaluating glinides or alpha glucosidase inhibitors were found. 17 trials included a majority of patients with previous cardiovascular history, 16 trials a majority of patients without. Compared to control, SGLT-2 inhibitors were associated with a decreased risk of overall mortality (OR = 0.84 [95% CrI: 0.74; 0.95]), SGLT-2 inhibitors and GLP-1 agonists with a decreased risk of MACE (OR = 0.89 [95% CrI: 0.81; 0.98] and OR = 0.88 [95% CrI: 0.81; 0.95], respectively). Compared to DPP-4 inhibitors, SGLT-2 inhibitors were associated with a decreased risk of overall mortality (OR = 0.82 [95% CrI: 0.69; 0.98]), GLP-1 agonists with a decreased risk of MACE (OR = 0.88 [95% CrI: 0.79; 0.99]). Insulin was also associated with an increased risk of MACE compared to GLP-1 agonists (OR = 1.19 [95% CrI: 1.01; 1.42]). Insulin and sulfonylureas were associated with an increased risk of severe hypoglycemia. In the trials including a majority of patients without previous CV history, the comparisons of SGLT-2 inhibitors, metformin and control did not showed significant differences on primary outcomes. We limited our analysis at the therapeutic class level.SGLT-2 inhibitors and GLP-1 agonists have the most beneficial effects, especially in T2D patients with previous CV diseases. Direct comparisons of SGLT-2 inhibitors, GLP-1 agonists and metformin are needed, notably in primary CV prevention.PROSPERO CRD42016043823." @default.
• W2953696397 created "2019-07-12" @default.
• W2953696397 creator A5001626252 @default.
• W2953696397 creator A5005222531 @default.
• W2953696397 creator A5011033386 @default.
• W2953696397 creator A5015801537 @default.
• W2953696397 creator A5023368803 @default.
• W2953696397 creator A5026143127 @default.
• W2953696397 creator A5027600205 @default.
• W2953696397 creator A5044479631 @default.
• W2953696397 creator A5059713827 @default.
• W2953696397 creator A5062484876 @default.
• W2953696397 creator A5082506046 @default.
• W2953696397 creator A5085014425 @default.
• W2953696397 creator A5086902696 @default.
• W2953696397 creator A5086968740 @default.
• W2953696397 creator A5090953396 @default.
• W2953696397 creator A5091690444 @default.
• W2953696397 date "2019-06-25" @default.
• W2953696397 modified "2023-10-16" @default.
• W2953696397 title "GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis" @default.
• W2953696397 cites W1128528964 @default.
• W2953696397 cites W1526927233 @default.
• W2953696397 cites W1617328014 @default.
• W2953696397 cites W178359339 @default.
• W2953696397 cites W1932961040 @default.
• W2953696397 cites W1975663485 @default.
• W2953696397 cites W1979409787 @default.
• W2953696397 cites W1997416444 @default.
• W2953696397 cites W2010699829 @default.
• W2953696397 cites W2040493457 @default.
• W2953696397 cites W2043807347 @default.
• W2953696397 cites W2056867141 @default.
• W2953696397 cites W2064130493 @default.
• W2953696397 cites W2071090755 @default.
• W2953696397 cites W2078482750 @default.
• W2953696397 cites W2094564105 @default.
• W2953696397 cites W2098923148 @default.
• W2953696397 cites W2113144077 @default.
• W2953696397 cites W2123424236 @default.
• W2953696397 cites W2127125241 @default.
• W2953696397 cites W2131490500 @default.
• W2953696397 cites W2133980496 @default.
• W2953696397 cites W2134177734 @default.
• W2953696397 cites W2135683342 @default.
• W2953696397 cites W2141199290 @default.
• W2953696397 cites W2142830692 @default.
• W2953696397 cites W2146264128 @default.
• W2953696397 cites W2159969745 @default.
• W2953696397 cites W2271771390 @default.
• W2953696397 cites W2274836352 @default.
• W2953696397 cites W2282578582 @default.
• W2953696397 cites W2302447233 @default.
• W2953696397 cites W2425644022 @default.
• W2953696397 cites W2473954980 @default.
• W2953696397 cites W2492974594 @default.
• W2953696397 cites W2519510391 @default.
• W2953696397 cites W2531816236 @default.
• W2953696397 cites W2564558295 @default.
• W2953696397 cites W2568525643 @default.
• W2953696397 cites W2588681363 @default.
• W2953696397 cites W2594590765 @default.
• W2953696397 cites W2611112923 @default.
• W2953696397 cites W2619082960 @default.
• W2953696397 cites W2621487800 @default.
• W2953696397 cites W2626446274 @default.
• W2953696397 cites W2754041380 @default.
• W2953696397 cites W2755083612 @default.
• W2953696397 cites W2773969925 @default.
• W2953696397 cites W2776015336 @default.
• W2953696397 cites W2792565546 @default.
• W2953696397 cites W2802245520 @default.
• W2953696397 cites W2894746763 @default.
• W2953696397 cites W2894993577 @default.
• W2953696397 cites W2896399430 @default.
• W2953696397 cites W2899764361 @default.
• W2953696397 cites W2900413769 @default.
• W2953696397 cites W47644979 @default.
• W2953696397 doi "https://doi.org/10.1371/journal.pone.0217701" @default.
• W2953696397 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6592598" @default.
• W2953696397 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31237921" @default.
• W2953696397 hasPublicationYear "2019" @default.
• W2953696397 type Work @default.
• W2953696397 sameAs 2953696397 @default.
• W2953696397 citedByCount "12" @default.
• W2953696397 countsByYear W29536963972020 @default.
• W2953696397 countsByYear W29536963972021 @default.
• W2953696397 countsByYear W29536963972022 @default.
• W2953696397 countsByYear W29536963972023 @default.
• W2953696397 crossrefType "journal-article" @default.
• W2953696397 hasAuthorship W2953696397A5001626252 @default.
• W2953696397 hasAuthorship W2953696397A5005222531 @default.
• W2953696397 hasAuthorship W2953696397A5011033386 @default.
• W2953696397 hasAuthorship W2953696397A5015801537 @default.
• W2953696397 hasAuthorship W2953696397A5023368803 @default.
• W2953696397 hasAuthorship W2953696397A5026143127 @default.
• W2953696397 hasAuthorship W2953696397A5027600205 @default.
• W2953696397 hasAuthorship W2953696397A5044479631 @default.

• next